Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

IMMUNODEFICIENCY DISORDERS

Complement inhibitor for therapy of CHAPLE

Nature Immunology volume 22, pages 106–108 (2021)Cite this article

Subjects

A new study shows successful immunotherapy of a detrimental gastrointestinal disease using the complement inhibitor eculizumab.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Activation and regulation of complement pathways.

References

  1. Ozen, A. et al. Nat. Immunol. https://doi.org/10.1038/s41590-020-00830-z (2021).

  2. Ozen, A. et al. N. Engl. J. Med. 377, 52–61 (2017).

    Article  CAS  Google Scholar 

  3. Kurolap, A. et al. N. Engl. J. Med. 377, 87–89 (2017).

    Article  Google Scholar 

  4. Lintner, K. E. et al. Front. Immunol. 7, 36 (2016).

    Article  Google Scholar 

  5. Barnum, S. & Schein, T. (eds.) The Complement FactsBook 2nd edn (Academic Press, 2018).

  6. Lublin, D. M. & Atkinson, J. P. Annu. Rev. Immunol. 7, 35–58 (1989).

    Article  CAS  Google Scholar 

  7. Dho, S. H., Lim, J. C. & Kim, L. K. Immune Netw. 18, e11 (2018).

    Article  Google Scholar 

  8. Lachmann, P. J. Immunol. Today 12, 312–315 (1991).

    Article  CAS  Google Scholar 

  9. Ekdahl, K. N. et al. Immunol. Rev. 274, 245–269 (2016).

    Article  CAS  Google Scholar 

  10. Savelli, S. L. et al. Front. Immunol. 10, 885 (2019).

    Article  CAS  Google Scholar 

  11. Mulvihill, E. et al. Lupus Sci. Med. 6, e000333 (2019).

    Article  Google Scholar 

  12. Kamitaki, N. et al. Nature 582, 577–581 (2020).

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The authors are supported by a National Institute of Arthritis Musculoskeletal and Skin Disease grant (R01 AR073311) from the National Institutes of Health.

Author information

Authors and Affiliations

  1. Abigail Wexner Research Institute and Division of Rheumatology, Nationwide Children’s Hospital and Department of Pediatrics, The Ohio State University, Columbus, OH, USA

    Chack-Yung Yu

  2. Department of Pediatrics and Department of Internal Medicine, The Ohio State University, Columbus, OH, USA

    Stacy P. Ardoin

  3. Division of Rheumatology, Nationwide Children’s Hospital and Wexner Medical Center, Columbus, OH, USA

    Stacy P. Ardoin

Authors
  1. Chack-Yung Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stacy P. Ardoin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Chack-Yung Yu or Stacy P. Ardoin.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yu, CY., Ardoin, S.P. Complement inhibitor for therapy of CHAPLE. Nat Immunol 22, 106–108 (2021). https://doi.org/10.1038/s41590-020-00842-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41590-020-00842-9

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing